1. HSP-70 as a nonspecific early marker in cisplatin ototoxicity
- Author
-
José María Verdaguer, A. Martín Marero, José Ángel González-García, Juan A. Vargas, José Ramón García-Berrocal, M. J. Citores, Almudena Trinidad, Rafael Ramírez-Camacho, and A. Puente
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Hearing Loss, Sensorineural ,Blotting, Western ,Antineoplastic Agents ,HSP72 Heat-Shock Proteins ,Biology ,Ototoxicity ,Western blot ,Heat shock protein ,medicine ,Evoked Potentials, Auditory, Brain Stem ,Animals ,HSP70 Heat-Shock Proteins ,Rats, Wistar ,Pathological ,Cisplatin ,medicine.diagnostic_test ,General Medicine ,medicine.disease ,Cochlea ,Rats ,Disease Models, Animal ,Otorhinolaryngology ,Ear, Inner ,Toxicity ,Biomarkers ,medicine.drug - Abstract
The great variety of pathological entities related to the presence of circulating HSP-70 suggests a nonspecific cellular damage. As the present study shows, positive results decrease with respect to the time elapsed after the injection of the ototoxic agent. HSP-70 appears as an early and transient marker that could permit early detection of inner ear damage.The aim of this study was to determine the presence of HSP-70 at different time points by means of Western blot immunoassay in the sera of rats treated with cisplatin.Thirty-six Wistar rats were intraperitoneally injected with cisplatin at a dose of 5 mg/kg and blood samples were collected at 7 and 90 days. Determination of HSP-70 was made by means of a modified Western blot immunoassay kit originally used for human HSP-70 antigen detection. A control group of 18 animals was used for comparison.Western blot was positive in 77.8% of the animals in the 7 days group, decreasing to a 44.4% in the 90 days group. In the control group, Western blot was positive in 5.5%.
- Published
- 2007